Subscribe to Search results

Dr Louis Aledort reported to the Congress of the International Societies of Hematology and of Blood Transfusion in Budapest in August 1982 that it was suspected in the US that Factor 8 had resulted in people with haemophilia dying of AIDS, and it was suspected that an infective agent in blood concentrates was the cause.

Published on:

The AIDS Literature contributor, Robert Hubbard, extracted articles and investigations in German literature on the risks of contracting HIV through contaminated blood products.

Published on:

The CDC published an update on AIDS among patients with haemophilia A, and found 95% of recently reported AIDS infections were either homosexually active men, intravenous drug abusers, Haitians and/or people with haemophilia.

Published on:

An article in The Lancet was published on the occurrence of AIDS in an infant who had had a blood transfusion at birth and the possibility of contracting AIDS in such a way.

Published on:

Dr Mark Winter (who regularly read the Morbidity and Mortality Weekly Report) told the Inquiry that: "Any clinician looking at this data would have to believe that AIDS was a transmissible disorder and that it could be transmitted by blood and by blood products."

Published on:

Ed Cutter wrote a memo to J Ryan, Carolyn Patrick, Wayne Johnson, Ralph Roussell and George Akin advising them to include an AIDS warning in their literature and on its packaging of its Factor 8 and Factor 9 products

Published on:

Sir Joseph Smith, former director of the NIBSC and thereafter the PHLS, provided a written statement to the Infected Blood Inquiry.

Published on:

Dr Charles Rizza published an epidemiological study of AIDS in patients with coagulation disorders in the UK and its relationship to transfusion with blood products.

Published on:

Cornelis Smith, coordinator of the Netherlands Haemophilia Society, provided a written statement to the Infected Blood Inquiry.

Published on:

The CDC published a report on "Immunodeficiency among Female Sexual Partners of Males with Acquired Immune Deficiency Syndrome (AIDS)".

Published on:

I Marshall, of Alpha Therapeutic, wrote to Professor Bloom in relation to AIDS and precautionary steps being introduced to minimise the risk of the disease being transmitted via donors to people with haemophilia, including donor screening and leafleting.

Published on:

Lederman et al published a report in the New England Journal of Medicine titled "Impaired cell-mediated immunity in patients with classic hemophilia".

Published on:

It was asserted in a meeting with Immuno that "it is not known if AIDS is caused by a virus or an attacker inimical to T cells".

Published on:

People with haemophilia who were without symptoms of HIV but who had received factor concentrates had abnormalities in their T cells, but those who had received cryoprecipitate did not.

Published on:

Medical News published an article entitled "Preventing AIDS transmission: should blood donors be screened?" reporting on the connection between AIDS and the infusion of blood and blood products.

Published on:

The Centers for Diseases Control published an article in its Morbidity and Mortality Weekly Report, which reported over 1,200 cases of AIDS from 34 states since June 1981, explained statistics and made reference to the parallel between AIDS and Hepatitis B.

Published on:

According to Dr Kingdon, the United States plasma collection centres tended to be located near areas where there was likely to be a population willing to spend 2-3 hours donating plasma for a small payment (near universities, army bases and in the lower socio-economic sections of a city).

Published on:

The size of pool used by Hyland/Travenol appears to have increased over time as, in his draft statement of 1990, Dr Kingdon referred to "start pool" sizes of up to 15,000 donations. He did not provide further details of when, how and why the pool size had changed.

Published on:

Dr Kingdon recorded that:"All importation stopped following the FDA direction that source plasma and the centres producing source plasma be licensed; the FDA would not inspect offshore sites which meant that imported plasma would not be approved plasma and therefore could no longer be used in the manufacture of blood products. As a result, since approximately 1978, all plasma used for the production of concentrates in the United States has been obtained from donors in the United States."

Published on:

There was a single centre in Belize, which was also licensed for fractionation (and hence should have been inspected) by the FDA.

Published on: